AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 17- Open
- $413.76
- 52-wk high
- $421.79
- High
- $416.03
- 52-wk low
- $264.02
- Low
- $410.50
- Prev close
- $417.84
Smart money
Earnings
Reported Aug 4, 2026
Earnings came in 12.3% above what analysts expected.
Financials
Sep 2025 to Jun 2026
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| RevenueTotal revenue | $9.56B | $9.90B | $8.62B | $10.05B |
| Cost of what it soldCost of revenue | $3.08B | $1.79B | $2.74B | $2.81B |
| Gross profit | $6.47B | $8.11B | $5.87B | $7.24B |
| What it spent | ||||
| Research and development | $1.90B | $2.15B | $1.72B | $1.87B |
| Sales and adminSelling, general and administrative | $1.72B | $1.95B | $1.60B | $1.75B |
| Other operating costsOperating costs not itemised in the filing's summary | $329.0M | $61.0M | -$113.0M | $116.0M |
| Total operating expenses | $3.95B | $4.16B | $3.21B | $3.73B |
| What was left | ||||
| Operating profitOperating income | $2.53B | $3.94B | $2.67B | $3.51B |
| Interest on debtInterest expense | $685.0M | $653.0M | $657.0M | $673.0M |
| Profit before tax | $3.92B | $1.51B | $2.08B | $2.77B |
| TaxIncome tax expense | $705.0M | $181.0M | $265.0M | $393.0M |
| Net profitNet income | $3.22B | $1.33B | $1.82B | $2.38B |
| EBITDAEarnings before interest, tax, depreciation, amortisation | $5.91B | $3.30B | $3.86B | $3.44B |
Technicals
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
73overbought
20D volatility
27%annualized
52-week range
$415.21$264.02$421.79
20D support
News
News
What the news says
50 articles · 7 days
Coverage is bullish
23 bullish · 26 neutral · 1 bearish
Tone of tracked coverage
Johnson & Johnson Hires Forbes Tate for Healthcare Lobbying
NeutralAug 17Amgen stock holds firm after Q2 sales raised the bar
BullishAug 17AMGN DCF Analysis: Intrinsic Value $296 vs Price $415
NeutralAug 17
